Radiant’s Multabody™ platform enables multi-valent, multi-specific antibodies that have the potential to transform the treatment of cancer, inflammation, infections and other heterogeneous diseases. This breakthrough in antibody engineering combines avidity – superior binding power – with multi-specificity to create multifunctional biologics with the potential to unlock biology not achievable with current antibodies. Multabodies are a new class of biologics built on a modular, fully human scaffold, simplifying development while leveraging existing antibody manufacturing processes. We are rapidly advancing this superior next-generation therapeutic platform for a variety of indications. Learn more at radiantbio.com.\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less